28.05.2012 • News • Pharmaceuticals • Mergers & Acquisitions (M&A) • Amylin

Drugmaker Amylin Draws Initial Bids

Biotechnology company Amylin Pharmaceuticals has drawn initial bids from drugmakers Merck & Co and Sanofi, Bloomberg News reported on Friday, citing anonymous sources.

The drugmakers made offers of at least $25 a share, which would value Amylin at more than $4 billion, the report said.

Sources have told Reuters that Amylin, which sells the diabetes drugs Byetta and Bydureon, started reaching out to potential buyers in April.

Merck declined to comment. Amylin and Sanofi were not immediately available to comment.

 

 

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature